Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/164851
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rodriguez, Celestino | - |
dc.contributor.author | Garcia, Trinidad | - |
dc.contributor.author | Areces, Débora | - |
dc.contributor.author | Fernandez, Estrella | - |
dc.contributor.author | Garcia-Noriega, Marcelino | - |
dc.contributor.author | Domingo i Pedrol, Joan Carles | - |
dc.date.accessioned | 2020-06-08T21:58:49Z | - |
dc.date.available | 2020-06-08T21:58:49Z | - |
dc.date.issued | 2019-04-14 | - |
dc.identifier.issn | 1176-6328 | - |
dc.identifier.uri | http://hdl.handle.net/2445/164851 | - |
dc.description.abstract | Background: Attention-deficit hyperactivity disorder (ADHD) is a complex disorder in terms of etiology, clinical presentation, and treatment outcome. Pharmacological and psychological interventions are recommended as primary treatments in ADHD; however, other nonpharmacological intervention such as a dietary supplementation with omega-3 polyunsaturated fatty acids (ω-3 PUFAs) has emerged as an attractive option. Purpose: The objective of the present study was to assess whether dietary supplementation with highly concentrated ω-3 docosahexaenoic acid (DHA) triglyceride may improve symptoms in ADHD. Method: A 6-month prospective double-blind placebo-controlled randomized clinical trial was designed in 66 patients with ADHD, aged between 6 and 18 years. Participants in the experimental group received a combination of ω-3 fatty acids (DHA 1,000 mg, eicosapentaenoic acid 90 mg, and docosapentaenoic acid 150 mg). Instruments included d2-test, AULA Nesplora, EDAH scales, and abbreviated Conner's Rating Scale. Results: In the cognitive test, between-group differences were not found, but within-group differences were of a greater magnitude in the DHA group. Between-group differences in favor of the DHA arm were observed in behavioral measures, which were already detected after 3 months of treatment. Results were not changed when adjusted by ADHD medication. Conclusions: This study provides further evidence of the beneficial effect of supplementation with ω-3 DHA in the management of ADHD. | - |
dc.format.extent | 17 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Dove Medical Press | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.2147/NDT.S206020 | - |
dc.relation.ispartof | Neuropsychiatric Disease and Treatment, 2019, vol. 15, p. 1193-1209 | - |
dc.relation.uri | https://doi.org/10.2147/NDT.S206020 | - |
dc.rights | cc-by-nc (c) Rodriguez, Celestino et al., 2019 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es | - |
dc.source | Articles publicats en revistes (Bioquímica i Biomedicina Molecular) | - |
dc.subject.classification | Trastorns per dèficit d'atenció amb hiperactivitat en els adults | - |
dc.subject.classification | Suplements nutritius | - |
dc.subject.other | Attention deficit disorder with hyperactivity in adults | - |
dc.subject.other | Dietary supplements | - |
dc.title | Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 698484 | - |
dc.date.updated | 2020-06-08T21:58:49Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31190827 | - |
Appears in Collections: | Articles publicats en revistes (Bioquímica i Biomedicina Molecular) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
698484.pdf | 350.96 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License